NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $68.74 -0.04 (-0.06 %) (As of 03/20/2019 11:18 AM ET)Previous Close$68.78Today's Range$68.46 - $69.4552-Week Range$29.85 - $80.92Volume2,314 shsAverage Volume810,935 shsMarket Capitalization$2.31 billionP/E Ratio35.30Dividend YieldN/ABeta1.47 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania. Receive BEAT News and Ratings via Email Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAT Previous Symbol CUSIPN/A CIK1574774 Webwww.gobio.com Phone610-729-7000Debt Debt-to-Equity Ratio0.62 Current Ratio2.96 Quick Ratio2.81Price-To-Earnings Trailing P/E Ratio35.30 Forward P/E Ratio36.96 P/E GrowthN/A Sales & Book Value Annual Sales$399.47 million Price / Sales5.78 Cash Flow$3.3160 per share Price / Cash Flow20.73 Book Value$9.32 per share Price / Book7.38Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$42.82 million Net Margins10.72% Return on Equity24.46% Return on Assets12.42%Miscellaneous Employees1,500 Outstanding Shares33,610,000Market Cap$2.31 billion Next Earnings Date4/24/2019 (Estimated) OptionableOptionable BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions What is BioTelemetry's stock symbol? BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT." How were BioTelemetry's earnings last quarter? BioTelemetry Inc (NASDAQ:BEAT) posted its quarterly earnings data on Thursday, February, 21st. The medical research company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.13. The medical research company had revenue of $103.60 million for the quarter, compared to analyst estimates of $102.84 million. BioTelemetry had a net margin of 10.72% and a return on equity of 24.46%. The business's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 earnings per share. View BioTelemetry's Earnings History. When is BioTelemetry's next earnings date? BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for BioTelemetry. What price target have analysts set for BEAT? 5 equities research analysts have issued 1-year target prices for BioTelemetry's stock. Their predictions range from $54.00 to $95.00. On average, they anticipate BioTelemetry's share price to reach $74.00 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for BioTelemetry. What is the consensus analysts' recommendation for BioTelemetry? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry. Has BioTelemetry been receiving favorable news coverage? Headlines about BEAT stock have trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioTelemetry earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of BioTelemetry's key competitors? Some companies that are related to BioTelemetry include Henry Schein (HSIC), Molina Healthcare (MOH), Davita (DVA), Sarepta Therapeutics (SRPT), Sartorius (SRT), Qiagen (QGEN), H. Lundbeck A/S- (HLUYY), Bausch Health Companies (BHC), bluebird bio (BLUE), Fisher & Paykel Healthcare (FPH), Beigene (BGNE), Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), Guardant Health (GH) and Jazz Pharmaceuticals (JAZZ). What other stocks do shareholders of BioTelemetry own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Alibaba Group (BABA), Square (SQ), salesforce.com (CRM), Adobe (ADBE), Veeva Systems (VEEV), Intuitive Surgical (ISRG) and ABIOMED (ABMD). Who are BioTelemetry's key executives? BioTelemetry's management team includes the folowing people: Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)Ms. Heather C. Getz, Exec. VP & CFO (Age 44)Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)Mr. Tim Raher, Sr. VP of HR Who are BioTelemetry's major shareholders? BioTelemetry's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.29%), Dimensional Fund Advisors LP (4.00%), Macquarie Group Ltd. (2.93%), Bank of New York Mellon Corp (2.32%), Ranger Investment Management L.P. (1.45%) and Northern Trust Corp (1.40%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry. Which institutional investors are selling BioTelemetry stock? BEAT stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Falcon Point Capital LLC, Pembroke Management LTD, Millennium Management LLC, Castleark Management LLC, Summit Creek Advisors LLC, Bank of New York Mellon Corp and First Trust Advisors LP. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry. Which institutional investors are buying BioTelemetry stock? BEAT stock was bought by a variety of institutional investors in the last quarter, including Legal & General Group Plc, BlackRock Inc., SG Americas Securities LLC, Geode Capital Management LLC, Geode Capital Management LLC, ClariVest Asset Management LLC, Hodges Capital Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for BioTelemetry. How do I buy shares of BioTelemetry? Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTelemetry's stock price today? One share of BEAT stock can currently be purchased for approximately $68.4817. How big of a company is BioTelemetry? BioTelemetry has a market capitalization of $2.30 billion and generates $399.47 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.94 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe. What is BioTelemetry's official website? The official website for BioTelemetry is http://www.gobio.com. How can I contact BioTelemetry? BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected] MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 296 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 544MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is insider trading?